Erythropoiesis stimulating agents and anaemia of end-stage renal disease

Cardiovascular and Hematological Agents in Medicinal Chemistry

Volumn 8, Issue 3, 2010, Pages 164-172

  Schmid, Holger ^a   Schiffl, Helmut ^b  

^a KfH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Anaemia; Chronic kidney disease; Erythropoiesis stimulating agents; Pure red cell aplasia

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIANEMIC AGENT; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; FERRITIN; FG 2216; FG 4592; HEMOGLOBIN; IMMUNOGLOBULIN; IRON; IRON COMPLEX; IRON DEXTRAN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ANAPHYLAXIS; ANEMIA; ANTIBODY PRODUCTION; ARTICLE; BLOOD TRANSFUSION; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DIALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG RESPONSE; ERYTHROCYTE APLASIA; ERYTHROPOIESIS; FERRITIN BLOOD LEVEL; GASTROINTESTINAL TOXICITY; HEMATOCRIT; HUMAN; HYPERTENSION; IRON DEFICIENCY; KIDNEY DISEASE; KIDNEY FAILURE; MAINTENANCE THERAPY; NEOPLASM; OUTCOME ASSESSMENT; PATHOGENESIS; RISK; THROMBOSIS; TREATMENT RESPONSE; TUMOR GROWTH;

ANEMIA; HEMATINICS; HUMANS; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS; RISK FACTORS;

EID: 77954698283     PISSN: 18715257     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152510791698398     Document Type: Article

References (55)

1. Levey, A.S.; Coresh, J.; Balk E.; Kausz, A.T.; Levin, A.; Steffes, M.W.; Hogg, R.J.; Perrone, R.D.; Lau, J.; Eknoyan, G. National Kidney Foundation. National Kidney Foundation practice guide- lines for chronic kidney disease, evaluation, classification and stratification. Ann. Intern. Med., 2003, 139, 137-147.
2. Coresh, J.; Selvin E.; Stevens, L.A.; Manzi, J.; Kusek, J.W.; Eggers, P.; Van Lente, F.; Levey, A.S. Prevalence of chronic kidney disease in the United States. JAMA, 2007, 298(17), 2038- 2047.
3. Coresh, J.; Astor, B.C.; Greene, T.; Eknoyan, G.; Levey, A.S. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am. J. Kidney Dis., 2003, 41, 1-12.
4. Kazmi, W.H.; Kausz, A.T.; Khan, S.; Abichandani, R.; Ruthazer, R.; Obrador, G.T.; Pereira, B.J. Anaemia, an early complication of chronic renal insufficiency. Am. J. Kidney Dis., 2001, 38(4), 803- 812.
5. Thomas, M.C.; MacIsaac, R.J.; Tsalamandris, C.; Molyneaux, L.; Goubina, I.; Fulcher, G.; Yue, D.; Jerums, G. The burden of anae- mia in type 2 diabetes and the role of nephropathy, a cross- sectional audit. Nephrol. Dial. Transplant., 2004; 19, 1792-1797.
6. Eschbach, J.W. Erythropoietin 1991--an overview. Am. J. Kidney Dis., 1991, 18(4 Suppl 1), 3-9.
7. Maxwell, P.H.; Osmond, M.K.; Pugh, C.W.; Heryet, A.; Nicholls, L.G.; Tan, C.C.; Doe, B.G.; Ferguson, D.J.; Johnson, M.H.; Ratcliffe PJ. Identification of the renal erythropoietin-producing cells using transgenic mice. Kidney Int., 1993, 44(5), 1149-1162.
8. Wideröe, T.E.; Sanengen, T.; Halvorsen, S. Erythropoietin and uremic toxicity during continuous ambulatory peritoneal dialysis. Kidney Int. Suppl., 1983, 16, S208-17.
9. Locatelli, F.; Del Vecchio, L.; Manzoni, C. Morbidity and mortal- ity on maintenance haemodialysis. Nephron., 1998, 80(4), 380-400.
10. Ma, J.Z.; Ebben, J.; Xia, H.; Collins, A.J. Hematocrit level and associated mortality in hemodialysis patients. J. Am. Soc. Nephrol., 1999, 10(3), 610-619.
11. Foley, R.N.; Parfrey, P.S.; Harnett, J.D.; Kent, G.M.; Murray, D.C.; Barre, P.E. The impact of anaemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am. J. Kidney Dis., 1996, 28(1), 53-61.
12. Shahani, S.; Braga-Basaria, M.; Maggio, M.; Basaria, S. Androgens and erythropoiesis, past and present. J. Endocrinol. Invest., 2009, 32(8), 704-716.
13. Eschbach, J.W.; Abdulhadi, M.H.; Browne, J.K.; Delano, B.G.; Downing, M.R.; Egrie, J.C.; Evans, R.W.; Friedman, E.A.; Graber, S.E.; Haley, N.R. Recombinant human erythropoietin in anemic pa- tients with end-stage renal disease. Results of a phase III multicen- ter clinical trial. Ann. Intern. Med., 1989, 111(12), 992-1000.
14. Locatelli, F.; Mann, J.F.; Aldigier, J.C.; Sanz Guajardo, D.; Schmidt, R.; Van Vlem, B.; Sulowicz, W.; Dougherty, F.C.; Beyer, U. C.E.R.A. safety profile, a pooled analysis in patients with chronic kidney disease. Clin. Nephrol., 2010, 73(2), 94-103.
15. Chanu, P.; Gieschke, R.; Charoin, J.E.; Pannier, A.; Reigner, B. Population Pharmacokinetic/Pharmacodynamic Model for a C.E.R.A. in Both ESA-Naive and ESA-Treated Chronic Kidney Disease Patients with Renal Anaemia. J. Clin. Pharmacol., 2010, 50(51), 507-520.
16. Macdougall, I.C. Novel erythropoiesis-stimulating agents, a new era in anaemia management. Clin. J. Am. Soc. Nephrol., 2008, 3(1), 200-207.
17. Locatelli, F.; Becker, H. Update on anaemia management in neph- rology including current guidelines on the use of erythropoiesis- stimulating agents and implications of the introduction of biosimi- lars. Oncologist, 2009, 14(Suppl 1),16-21.
18. Mellstedt, H.; Niederwieser, D.; Ludwig, H. The challenge of biosimilars. Ann. Oncol., 2008, 19(3), 411-419.
19. Macdougall, I.C. Hematide, a novel peptide-based erythropoiesis- stimulating agent for the treatment of anaemia. Curr. Opin. Investig. Drugs, 2008, 9(9), 1034-1047.
20. Foley, R.N. Emerging erythropoiesis-stimulating agents. Nat. Rev. Nephrol., 2010, 6(4), 218-223.
21. K/DOQI Clinical Practice Guidelines and Clinical Practice Recommendations for anaemia in chronic kidney disease. Am. J. Kidney Dis., 2006, 47(suppl 3), S1.
22. Locatelli, F.; Aljama, P.; Bárány, P.; Canaud, B.; Carrera, F.; Eckardt, K.U.; Hörl, W.H.; Macdougal, I.C.; Macleod, A.; Wiecek, A.; Cameron, S. European Best Practice Guidelines Working Group. Revised European best practice guidelines for the manage- ment of anaemia in patients with chronic renal failure. Nephrol. Dial. Transplant., 2004, 19(Suppl 2), ii1-47.
23. Schmid, H.; Hartmann, B.; Schiffl, H. Adherence to prescribed oral medication in adult patients undergoing chronic hemodialysis, a critical review of the literature. Eur. J. Med. Res., 2009, 14(5), 185- 190.
24. Katzir, Z.; Boaz, M.; Backshi, I.; Cernes, R.; Barnea, Z.; Biro, A. Medication Apprehension and Compliance among Dialysis Patients - A Comprehensive Guidance Attitude. Nephron. Clin. Pract., 2009, 114(2), c151-c157.
25. Elliott, J.; Mishler, D.; Agarwal, R. Hyporesponsiveness to erythropoietin, causes and management. Adv. Chronic Kidney Dis., 2009, 16(2), 94-100.
26. NKF-K/DOQI Clinical Practice Guidelines.; 2007 update on haemoglobin target. Am. J. Kidney Dis., 2007, 50, 474.
27. Besarab, A.; Bolton, W.K.; Browne, J.K.; Egrie, J.C.; Nissenson, A.R.; Okamoto, D.M.; Schwab, S.J.; Goodkin, D.A. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N. Engl. J. Med., 1998, 339(9), 584-590.
28. Singh, A.K.; Szczech, L.; Tang, K.L.; Barnhart, H.; Sapp, S.; Wolfson, M.; Reddan, D; CHOIR Investigators. Correction of anaemia with epoetin alfa in chronic kidney disease. N. Engl. J. Med., 2006, 355(20), 2085-2098.
29. Drüeke, T.B.; Locatelli, F.; Clyne, N.; Eckardt, K.U.; Macdougall, I.C.; Tsakiris, D.; Burger, H.U.; Scherhag, A. CREATE Investiga- tors. Normalization of hemoglobin level in patients with chronic kidney disease and anaemia. N. Engl. J. Med., 2006, 355(20), 2071- 2084.
30. Pfeffer, M.A.; Burdmann, E.A.; Chen, C.Y.; Cooper, M.E.; de Zeeuw, D.; Eckardt, K.U.; Feyzi, J.M.; Ivanovich, P.; Kewalra- mani, R.; Levey, A.S.; Lewis, E.F.; McGill, J.B.; McMurray, J.J.; Parfrey, P.; Parving, H.H.; Remuzzi, G.; Singh, A.K.; Solomon, S.D.; Toto, R. TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N. Engl. J. Med., 2009, 361(21), 2019-2032.
31. Gilbertson, D.T.; Ebben, J.P.; Foley, R.N.; Weinhandl, E.D.; Bradbury, B.D.; Collins, A.J. Hemoglobin level variability, asso- ciations with mortality. Clin. J. Am. Soc. Nephrol., 2008, 3(1), 133- 138.
32. Streja, E.; Kovesdy, C.P.; Greenland, S.; Kopple, J.D.; McAllister, C.J.; Nissenson, A.R.; Kalantar-Zadeh, K. Erythropoietin, iron de- pletion and relative thrombocytosis, a possible explanation for he- moglobin-survival paradox in hemodialysis. Am. J. Kidney Dis., 2008, 52(4), 727-736.
33. Szczech, L.A.; Barnhart, H.X.; Inrig, J.K.; Reddan, D.N.; Sapp, S.; Califf, R.M.; Patel, U.D.; Singh, A.K. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int., 2008, 74(6), 791-798.
34. Verga Falzacappa, M.V.; Muckenthaler, M.U. Hepcidin, iron- hormone and anti-microbial peptide. Gene, 2005, 364, 37-44.
35. Andrews, N.C. Anaemia of inflammation, the cytokine-hepcidin link. J. Clin. Invest., 2004, 113(9), 1251-1253.
36. Kemna, E.H.; Tjalsma, H.; Willems, H.L.; Swinkels, D.W. Hepcidin, from discovery to differential diagnosis. Haematologica, 2008, 93(1), 90-97.
37. Ashby, D.R.; Gale, D.P.; Busbridge, M.; Murphy, K.G.; Duncan, N.D.; Cairns, T.D.; Taube, D.H.; Bloom, S.R.; Tam, F.W.; Chap- man, R.S.; Maxwell, P.H.; Choi, P. Plasma hepcidin levels are ele- vated but responsive to erythropoietin therapy in renal disease. Kidney Int., 2009, 75(9), 976-981.
38. Ashby, D.R.; Gale, D.P.; Busbridge, M.; Murphy, K.G.; Duncan, N.D.; Cairns, T.D.; Taube, D.H.; Bloom, S.R.; Tam, F.W.; Chap- man, R.; Maxwell, P.H.; Choi, P. Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin. Haematologica, 2010, 95(3), 505-508.
39. Brugnara, C.; Schiller, B.; Moran, J. Reticulocyte hemoglobin equivalent (Ret He) and assessment of iron-deficient states. Clin. Lab. Haematol., 2006, 28(5), 303-308.
40. Kalantar-Zadeh, K.; Kalantar-Zadeh, K.; Lee, G.H. The fascinating but deceptive ferritin, to measure it or not to measure it in chronic kidney disease? Clin. J. Am. Soc. Nephrol., 2006, 1(Suppl 1), S9-18.
41. Coyne, D.W.; Kapoian, T.; Suki, W.; Singh, A.K.; Moran, J.E.; Dahl, N.V.; Rizkala, A.R; DRIVE Study Group. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation, results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J. Am. Soc. Nephrol., 2007, 18(3), 975-984.
42. Kapoian, T.; O'Mara, N.B.; Singh, A.K.; Moran, J.; Rizkala, A.R.; Geronemus, R.; Kopelman, R.C.; Dahl, N.V.; Coyne, D.W. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J. Am. Soc. Nephrol., 2008, 19(2), 372-379.
43. Pollak, V.E.; Lorch, J.A.; Shukla, R.; Satwah, S. The importance of iron in long-term survival of maintenance hemodialysis patients treated with epoetin-alfa and intravenous iron, analysis of 9.5 years of prospectively collected data. BMC Nephrol., 2009, 10, 6.
44. Macdougall, I.C. Iron supplementation in the non-dialysis chronic kidney disease (ND-CKD) patient, oral or intravenous? Curr. Med. Res. Opin., 2010, 26(2), 473-482.
45. Mircescu, G.; Gârneata, L.; Capusa, C.; Ursea, N. Intravenous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure patients. Nephrol. Dial. Transplant., 2006, 21(1), 120-124.
46. Vaziri, N.D. Mechanism of erythropoietin-induced hypertension. Am. J. Kidney Dis., 1999, 33(5), 821-828.
47. Churchill, D.N.; Muirhead, N.; Goldstein, M.; Posen, G.; Fay, W.; Beecroft, M.L.; Gorman, J.; Taylor, D.W. Probability of thrombo- sis of vascular access among hemodialysis patients treated with re- combinant human erythropoietin. J. Am. Soc. Nephrol., 1994, 4(10), 1809-1813.
48. Hershman, D.L.; Buono, D.L.; Malin, J.; McBride, R.; Tsai, W.Y.; Neugut, A.I. Patterns of use and risks associated with erythropoie- sis-stimulating agents among Medicare patients with cancer. J. Natl. Cancer Inst., 2009, 101(23), 1633-1641.
49. Pollock, C.; Johnson, DW.; Hörl, W.H.; Rossert, J.; Casadevall, N.; Schellekens, H.; Delage, R.; De Francisco, A.; Macdougall, I.; Thorpe, R.; Toffelmire, E. Pure red cell aplasia induced by erythro- poiesis-stimulating agents. Clin. J. Am. Soc. Nephrol., 2008, 3(1), 193-199.
50. Macdougall, I.C.; Rossert, J.; Casadevall, N.; Stead, R.B.; Duliege, A.M.; Froissart, M.; Eckardt, K.U. A peptide-based erythropoietin- receptor agonist for pure red-cell aplasia. N. Engl. J. Med., 2009, 361(19), 1848-1855.
51. Bennett, C.L.; Luminari, S.; Nissenson, A.R.; Tallman, M.S.; Klinge, S.A.; McWilliams, N.; McKoy, J.M.; Kim, B.; Lyons, E.A.; Trifilio, S.M.; Raisch, D.W.; Evens, A.M.; Kuzel, T.M.; Schumock, G.T.; Belknap, S.M.; Locatelli, F.; Rossert, J.; Casadevall, N. Pure red-cell aplasia and epoetin therapy. N. Engl. J. Med., 2004, 351(14), 1403-1408.
52. McKoy, J.M.; Stonecash, R.E.; Cournoyer, D.; Rossert, J.; Nissen- son, A.R.; Raisch, D.W.; Casadevall, N.; Bennett, C.L. Epoetin- associated pure red cell aplasia, past.; present.; and future consid- erations.Transfusion, 2008, 48(8), 1754-1762.
53. Henke, M.; Laszig, R.; Rübe, C.; Schäfer, U.; Haase, K.D.; Schilcher, B.; Mose, S.; Beer, K.T.; Burger, U.; Dougherty, C.; Frommhold, H. Erythropoietin to treat head and neck cancer pa- tients with anaemia undergoing radiotherapy, randomised, double- blind, placebo-controlled trial. Lancet, 2003, 362(9392), 1255- 1260.
54. Crouch, Z.; DeSantis, E.R. Use of erythropoietin-stimulating agents in breast cancer patients, a risk review. Am. J. Health Syst. Pharm., 2009, 66(13), 1180-1185.
55. Hadland, B.K.; Longmore, G.D. Erythroid-stimulating agents in cancer therapy, potential dangers and biologic mechanisms. J. Clin. Oncol., 2009, 27(25), 4217-4226.